EP
SRRA

Eversept Partners’s Sierra Oncology, Inc. Common Stock SRRA Stock Holding History

Eversept Partners’s Portfolio SRRA Stock Details SRRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1,675
Closed -$250K – 64
2017
Q4 		$250K Buy
+1,675
New +$161K 0.14% 44

Other funds holding SRRA

FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Eversept Partners's SRRA Position: Q1 2018 in Review

Eversept Partners sold out of Sierra Oncology, Inc. Common Stock (SRRA) in Q1 2018, closing a stake of 1,675 shares — an estimated $250K sold.

Eversept Partners first reported a position in SRRA in Q4 2017 and held it in 1 quarter. The position peaked at $250K in Q4 2017. 73 funds tracked by Wall St. Rank hold SRRA as of Q1 2018.

  • Eversept Partners reported no remaining Sierra Oncology, Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
  • Eversept Partners sold 1,675 Sierra Oncology, Inc. Common Stock shares in Q1 2018, an estimated $250K.
  • Eversept Partners first reported a position in Sierra Oncology, Inc. Common Stock in Q4 2017 and held it in 1 quarter.
  • Eversept Partners's Sierra Oncology, Inc. Common Stock position peaked at $250K in Q4 2017.
  • 73 funds tracked by Wall St. Rank held Sierra Oncology, Inc. Common Stock as of Q1 2018.

Based on Eversept Partners's 13F filing for Q1 2018, filed 14 May 2018.